華顯光電(00334.HK):2022年歸母淨利1.69億元 同比下降12.5%
格隆匯3月30日丨華顯光電(00334.HK)發佈公吿,截至2022年12月31日止年度,持續經營業務收入為人民幣42.08億元,同比下降27.9%;毛利為人民幣3.44億元,同比下降30.5%;母公司擁有者應占溢利為人民幣1.69億元,同比下降12.5%,基本每股盈利8.06分。
回顧期內,銷售業務為集團的主要持續經營業務,集團的銷售類模組銷量達5250萬片,佔集團總銷量96.9%,相關營業額為人民幣41.73億元。與此同時,由於智能手機市場需求下降,上游供應鏈的利潤空間減少,集團於回顧期內整體平均銷售價格同比減少12.7%至人民幣79.4元(不包括加工模組)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.